Floatz logo

Therapeutic Asset Ratings

13,155 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Mucosal Melanoma
Fred Hutchinson Cancer CenterP2B (62)
Nivolumab
Ocular Melanoma
University of Michigan Rogel Cancer CenterP2B (62)
Nivolumab
Osteosarcoma
Instituto do Cancer do Estado de São PauloP2B (62)
Nivolumab
Neoplasm With Perivascular Epithelioid Cell Differentiation
Sarcoma Oncology Research Center, LLCP2B (62)
Nivolumab
B-Cell Chronic Lymphocytic Leukemia
M.D. Anderson Cancer CenterP2B (62)
Nivolumab
Small Cell Lung Carcinoma
Bristol-Myers SquibbP2B (62)
Nivolumab
Squamous Cell Carcinoma
Diwakar DavarP2B (62)
NORVIR
Long COVID-19
Kanecia Obie ZimmermanP2B (62)
Obinutuzumab
Burkitt Lymphoma
Acepodia Biotech, Inc.P2B (62)
Olaparib
Ovarian Neoplasm
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2B (62)
Olutasidenib
Myelodysplastic Syndrome
National Cancer Institute (NCI)P2B (62)
Onfasprodil
Depressive Disorder
Novartis PharmaceuticalsP2B (62)
Palbociclib
HER2 Positive Breast Carcinoma
Jiangsu Alphamab Biopharmaceuticals Co., LtdP2B (62)
Palbociclib
Refractory Malignant Neoplasm
Brown UniversityP2B (62)
PANITUMUMAB
Lung Cancer
Institut de Recherches Internationales ServierP2B (62)
PANITUMUMAB
Non-Small Cell Lung Carcinoma
Astellas Pharma IncP2B (62)
Paxlovid
Long COVID-19
Kanecia Obie ZimmermanP2B (62)
PBR28
Alzheimer Disease
University of PennsylvaniaP2B (62)
Pembrolizumab
Lung Carcinoma
Essen BiotechP2B (62)
Pembrolizumab
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (62)
Pembrolizumab
Follicular Lymphoma
Mayo ClinicP2B (62)
Pembrolizumab
Lung Adenocarcinoma
Rabin Medical CenterP2B (62)
Pembrolizumab
Primary Central Nervous System Lymphoma
Dana-Farber Cancer InstituteP2B (62)
Pembrolizumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (62)
Pembrolizumab
Skin Cancer
Institute of Oncology LjubljanaP2B (62)
Showing 1251 to 1275 of 13,155 assets
PreviousPage 51 of 527Next